Deal Making
Featured on Deal Making
Hemophilia A-OK! FTC thumbs up effectively closes Roche’s $4.3bn Spark buy
RegulationsHemophilia A-OK! FTC thumbs up effectively closes Roche’s $4.3bn Spark buyHemophilia A-OK! FTC thumbs up effectively closes Roche’s $4.3bn Spark buy
There is no risk of competitive harm between Roche’s approved hemophila A monoclonal antibody and Spark’s gene therapy candidates, say competition bodies.
More from Deal Making
Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.